BeOne Medicines AG (HKG:6160)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
163.70
+6.30 (4.00%)
Jun 18, 2026, 4:08 PM HKT

BeOne Medicines AG Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, BeOne Medicines AG stock has a consensus rating of "Strong Buy" and an average price target of $253.82. The average 1-year stock price forecast is 55.05% higher than the current stock price, while the lowest is $212.44 (+29.77%) and the highest is $298.21 (+82.17%).

Price Target: $253.82 (+55.05%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$212.44$253.82$247.10$298.21
Change+29.77%+55.05%+50.95%+82.17%

Analyst Ratings

The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy141414141414
Buy233333
Hold000000
Sell000000
Strong Sell000000
Total161717171717

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
CICC
No rating
CICC
Buy
Maintains
$250.00
BuyMaintains$250.00+52.72%Jun 3, 2026
Unknown Analyst
Citi
No rating
Citi
Buy
Maintains
$271.80
BuyMaintains$271.80+66.04%Jun 2, 2026
Unknown Analyst
UBS
No rating
UBS
Buy
Maintains
$279.00
BuyMaintains$279.00+70.43%May 26, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
$243.80
BuyMaintains$243.80+48.93%May 21, 2026
Unknown Analyst
Citic Securities
No rating
Citic Securities
Buy
Maintains
$240.00$234.00
BuyMaintains$240.00$234.00+42.94%May 12, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
45.32B
from 37.37B
Increased by 21.27%
Revenue Next Year
52.00B
from 45.32B
Increased by 14.74%
EPS This Year
3.51
from 1.33
Increased by 164.37%
EPS Next Year
5.37
from 3.51
Increased by 52.77%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
7.47B9.77B17.43B27.81B37.37B45.32B
Revenue Growth
270.56%30.69%78.53%59.51%34.37%21.27%
Gross Profit
6.42B7.79B14.74B23.48B32.70B39.55B
Gross Margin
85.98%79.77%84.55%84.41%87.49%87.28%
Operating Income
-9.14B-12.34B-8.56B-4.15B3.13B5.98B
Net Income
-9.26B-13.82B-6.25B-4.71B2.01B5.33B
EPS
----1.333.51
EPS Growth
-----164.37%
Forward PE
-----40.25
Free Cash Flow
-7.65B-6.51B-9.03B-2.71B4.98B4.82B
No. Analysts
-----34
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High47.9B
Avg45.3B
Low43.4B

Revenue Growth

Revenue Growth202620272028
High
28.1%
Avg
21.3%
Low
16.3%

EPS Forecast

EPS202620272028
High5.10
Avg3.51
Low2.94

EPS Growth

EPS Growth202620272028
High
283.7%
Avg
164.4%
Low
121.1%